§ 524.1484 Neomycin, prednisolone, and tetracaine otic suspension.

§ 524.1484f Neomycin, prednisolone, and tetracaine otic suspension.

§ 524.1484g Neomycin, thiamethazole, and dexamethasone solution.

§ 524.1484h Neomycin, penicillin, polymyxin B, and hydrocortisone suspension.

§ 524.1484i Neomycin and hydrocortisone ointment.

§ 524.1484j Neomycin and prednisolone ophthalmic ointment.

§ 524.1484k Prednisolone and neomycin suspension.

§ 524.1580 Nitrofurazone topical dosage forms.

§ 524.1580a Nitrofurazone ointment.

§ 524.1580b Nitrofurazone soluble powder.

§ 524.1580c Nitrofurazone and butacaine ointment.

§ 524.1600 Nystatin ophthalmic and topical dosage forms.

§ 524.1600a Nystatin, neomycin, thiostrepton, and triamcinolone ointment.

§ 524.1600b Nystatin, neomycin, thiostrepton, and triamcinolone ophthalmic ointment.

§ 524.1610 Orbifloxacin, mometasone furoate monohydrate, and posaconazole suspension.

§ 524.1662 Oxytetracycline ophthalmic and topical dosage forms.

§ 524.1662a Oxytetracycline and hydrocortisone spray.

§ 524.1662b Oxytetracycline and polymyxin B ophthalmic ointment.

§ 524.1742 N-Mercaptomethyl phthalimide S-(O,O-dimethyl phosphorodithioate) emulsifiable liquid.

§ 524.1982 Proparacaine ophthalmic solution.

§ 524.2098 Selamectin.

§ 524.2101 Selenium disulfide suspension.

§ 524.2350 Tolnaftate cream.

§ 524.2482 Triamcinolone spray.

§ 524.2483 Triamcinolone cream.

§ 524.2620 Liquid crystalline trypsin, Peru balsam, castor oil.


SOURCE: 40 FR 13873, Mar. 27, 1975, unless otherwise noted.

§ 524.155 Bacitracin, neomycin, and polymyxin B ophthalmic ointment.

(a) Specifications. Each gram of ointment contains:

1. 500 units of bacitracin, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B sulfate; or

2. 400 units of bacitracin zinc, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B sulfate.

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter as follows:

1. No. 054771 for use of product described in paragraph (a)(1) as in paragraph (c) of this section.

2. Nos. 000061 and 043264 for use of product described in paragraph (a)(2) as in paragraph (c) of this section.

(c) Conditions of use in dogs and cats. —

1. Amount. Apply a thin film over the cornea 3 or 4 times daily.

2. Indications for use. Treatment of superficial bacterial infections of the eyelid and conjunctiva of dogs and cats when due to susceptible organisms.

3. Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.390 Chloramphenicol ophthalmic ointment.

(a) Specifications. Each gram contains 10 milligrams chloramphenicol.

(b) Sponsors. See Nos. 043264 and 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. Apply every 3 hours around the clock for 48 hours, after which night instillations may be omitted.

(2) Indications for use. For treatment of bacterial conjunctivitis caused by pathogens susceptible to chloramphenicol.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.402 Chlorhexidine.

(a) Specifications. Each gram contains 10 milligrams chlorhexidine acetate.

(b) Sponsors. See Nos. 054771 and 058829 in § 510.600(c) of this chapter.

(c) Conditions of use—

(1) Indications for use. For use as a topical antiseptic ointment for surface wounds.

(2) Limitations. Do not use in horses intended for human consumption.


§ 524.450 Clotrimazole.

(a) Specifications. Each gram contains 10 milligrams clotrimazole.

(b) Sponsors. See No. 000859 in § 510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. Apply ¼-inch ribbon of cream per square inch of lesion once daily for 2 to 4 weeks.

(2) Indications for use. For the treatment of fungal infections of dogs and cats caused by Microsporum canis and Trichophyton mentagrophytes.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 48128, July 18, 1980, as amended at 79 FR 10967, Feb. 27, 2014]

§ 524.463 Copper naphthenate.

(a) Amount. The drug is a 37.5 percent solution of copper naphthenate.

(b) Sponsors. See Nos. 017135, 054771, and 058829 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—

(1) Indications for use. As an aid in treating horses and ponies for thrush caused by organisms susceptible to copper naphthenate.

(2) Limitations. Use on horses and ponies only. Avoid contact around eyes. Do not contaminate feed. Do not use in horses intended for human consumption.


§ 524.575 Cyclosporine ophthalmic ointment.

(a) Specifications. Each gram of ointment contains 2 milligrams of cyclosporine.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. Apply a ¼-inch strip of ointment directly on the cornea or into the conjunctival sac of the affected eye(s) every 12 hours.

(2) Indications for use. For management of chronic keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK) in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.590 Diclofenac.

(a) Specifications. Each gram of cream contains 10 milligrams diclofenac sodium.

(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—

(1) Amount. Apply a 5-inch (5″) ribbon of